Statins reduce new-onset atrial fibrillation in a first-time myocardial infarction population: a nationwide propensity score-matched study

Casper N Bang; Gunnar H Gislason; Anders M Greve; Christian Torp-Pedersen; Lars Køber; Kristian Wachtell

doi:10.1177/2047487312462804

Statins reduce new-onset atrial fibrillation in a first-time myocardial infarction population: a nationwide propensity score-matched study

Casper N Bang, Gunnar H Gislason, Anders M Greve, Christian Torp-Pedersen, Lars Køber, Kristian Wachtell

11 Citations (Scopus)

Abstract

Aim: To evaluate the effect of statins on reducing new-onset atrial fibrillation (AF) in a large real-world post-myocardial infarction (MI) population. Subsequently, to test if different statin doses, various types and compliance affected the incidence of new-onset AF post MI. Methods: All patients with first-time acute MI between 1997 and 2009 in Denmark and claimed prescriptions of statins after discharge were identified from the Danish nationwide administrative registers. Patients with a history of AF were excluded. Risk of new-onset AF according to statin use were analysed by multivariable time-dependent Cox regressions models adjusted for age, gender, year, concomitant medication, and comorbidity, and additionally in a propensity scorematched analysis. Results: A total of 89,703 patients with average follow up of 5.0±3.5 years were included in this study. In the 56,044 patients receiving statins, 5698 (10%) had new-onset AF vs. 5010 (15%) in the 33,659 patients serving as controls. The adjusted Cox regression analysis showed significant reduction in new-onset AF (HR 0.83, 95% CI 0.80-0.87, p≤0.001) in statin users. Adjustment for propensity score yielded nearly identical results (HR 0.82, 95% CI 0.78-0.85, p≤0.001). Furthermore, patients compliant to statin treatment had significant reduction in new-onset AF (HR 0.84, 95% CI 0.80- 0.87, p≤0.001). Finally, simvastatin and atorvastatin were significantly more effective than pravastatin (both p≤0.01) in reducing new-onset AF. Conclusions: Statin therapy was significantly associated with less new-onset AF in a nationwide cohort of post-MI patients. Furthermore, statins showed a type-dependent effect in preventing new-onset AF. These results support the beneficial effect of statin therapy beyond lipid lowering in patients with MI and underline the importance of statin adherence and choice of statin type.

Original language	English
Journal	European Journal of Preventive Cardiology
Volume	21
Issue number	3
Pages (from-to)	330-8
Number of pages	9
ISSN	2047-4873
DOIs	https://doi.org/10.1177/2047487312462804
Publication status	Published - Mar 2014

Keywords

Age Factors
Aged
Aged, 80 and over
Atrial Fibrillation
Chi-Square Distribution
Comorbidity
Denmark
Female
Heptanoic Acids
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Male
Medication Adherence
Middle Aged
Multivariate Analysis
Myocardial Infarction
Polypharmacy
Pravastatin
Propensity Score
Proportional Hazards Models
Pyrroles
Registries
Retrospective Studies
Risk Factors
Sex Factors
Simvastatin
Time Factors
Treatment Outcome

Access to Document

10.1177/2047487312462804

Cite this

Statins reduce new-onset atrial fibrillation in a first-time myocardial infarction population : a nationwide propensity score-matched study. / Bang, Casper N ; Gislason, Gunnar H; Greve, Anders M et al.

In: European Journal of Preventive Cardiology, Vol. 21, No. 3, 03.2014, p. 330-8.

Research output: Contribution to journal › Journal article › Research › peer-review

@article{7782e11999b94b5b93bc2803761ce14a,

title = "Statins reduce new-onset atrial fibrillation in a first-time myocardial infarction population: a nationwide propensity score-matched study",

abstract = "Aim: To evaluate the effect of statins on reducing new-onset atrial fibrillation (AF) in a large real-world post-myocardial infarction (MI) population. Subsequently, to test if different statin doses, various types and compliance affected the incidence of new-onset AF post MI. Methods: All patients with first-time acute MI between 1997 and 2009 in Denmark and claimed prescriptions of statins after discharge were identified from the Danish nationwide administrative registers. Patients with a history of AF were excluded. Risk of new-onset AF according to statin use were analysed by multivariable time-dependent Cox regressions models adjusted for age, gender, year, concomitant medication, and comorbidity, and additionally in a propensity scorematched analysis. Results: A total of 89,703 patients with average follow up of 5.0±3.5 years were included in this study. In the 56,044 patients receiving statins, 5698 (10%) had new-onset AF vs. 5010 (15%) in the 33,659 patients serving as controls. The adjusted Cox regression analysis showed significant reduction in new-onset AF (HR 0.83, 95% CI 0.80-0.87, p≤0.001) in statin users. Adjustment for propensity score yielded nearly identical results (HR 0.82, 95% CI 0.78-0.85, p≤0.001). Furthermore, patients compliant to statin treatment had significant reduction in new-onset AF (HR 0.84, 95% CI 0.80- 0.87, p≤0.001). Finally, simvastatin and atorvastatin were significantly more effective than pravastatin (both p≤0.01) in reducing new-onset AF. Conclusions: Statin therapy was significantly associated with less new-onset AF in a nationwide cohort of post-MI patients. Furthermore, statins showed a type-dependent effect in preventing new-onset AF. These results support the beneficial effect of statin therapy beyond lipid lowering in patients with MI and underline the importance of statin adherence and choice of statin type.",

keywords = "Age Factors, Aged, Aged, 80 and over, Atrial Fibrillation, Chi-Square Distribution, Comorbidity, Denmark, Female, Heptanoic Acids, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Male, Medication Adherence, Middle Aged, Multivariate Analysis, Myocardial Infarction, Polypharmacy, Pravastatin, Propensity Score, Proportional Hazards Models, Pyrroles, Registries, Retrospective Studies, Risk Factors, Sex Factors, Simvastatin, Time Factors, Treatment Outcome",

author = "Bang, {Casper N} and Gislason, {Gunnar H} and Greve, {Anders M} and Christian Torp-Pedersen and Lars K{\o}ber and Kristian Wachtell",

year = "2014",

month = mar,

doi = "10.1177/2047487312462804",

language = "English",

volume = "21",

pages = "330--8",

journal = "European Journal of Preventive Cardiology",

issn = "2047-4873",

publisher = "SAGE Publications",

number = "3",

}

TY - JOUR

T1 - Statins reduce new-onset atrial fibrillation in a first-time myocardial infarction population

T2 - a nationwide propensity score-matched study

AU - Bang, Casper N

AU - Gislason, Gunnar H

AU - Greve, Anders M

AU - Torp-Pedersen, Christian

AU - Køber, Lars

AU - Wachtell, Kristian

PY - 2014/3

Y1 - 2014/3

N2 - Aim: To evaluate the effect of statins on reducing new-onset atrial fibrillation (AF) in a large real-world post-myocardial infarction (MI) population. Subsequently, to test if different statin doses, various types and compliance affected the incidence of new-onset AF post MI. Methods: All patients with first-time acute MI between 1997 and 2009 in Denmark and claimed prescriptions of statins after discharge were identified from the Danish nationwide administrative registers. Patients with a history of AF were excluded. Risk of new-onset AF according to statin use were analysed by multivariable time-dependent Cox regressions models adjusted for age, gender, year, concomitant medication, and comorbidity, and additionally in a propensity scorematched analysis. Results: A total of 89,703 patients with average follow up of 5.0±3.5 years were included in this study. In the 56,044 patients receiving statins, 5698 (10%) had new-onset AF vs. 5010 (15%) in the 33,659 patients serving as controls. The adjusted Cox regression analysis showed significant reduction in new-onset AF (HR 0.83, 95% CI 0.80-0.87, p≤0.001) in statin users. Adjustment for propensity score yielded nearly identical results (HR 0.82, 95% CI 0.78-0.85, p≤0.001). Furthermore, patients compliant to statin treatment had significant reduction in new-onset AF (HR 0.84, 95% CI 0.80- 0.87, p≤0.001). Finally, simvastatin and atorvastatin were significantly more effective than pravastatin (both p≤0.01) in reducing new-onset AF. Conclusions: Statin therapy was significantly associated with less new-onset AF in a nationwide cohort of post-MI patients. Furthermore, statins showed a type-dependent effect in preventing new-onset AF. These results support the beneficial effect of statin therapy beyond lipid lowering in patients with MI and underline the importance of statin adherence and choice of statin type.

AB - Aim: To evaluate the effect of statins on reducing new-onset atrial fibrillation (AF) in a large real-world post-myocardial infarction (MI) population. Subsequently, to test if different statin doses, various types and compliance affected the incidence of new-onset AF post MI. Methods: All patients with first-time acute MI between 1997 and 2009 in Denmark and claimed prescriptions of statins after discharge were identified from the Danish nationwide administrative registers. Patients with a history of AF were excluded. Risk of new-onset AF according to statin use were analysed by multivariable time-dependent Cox regressions models adjusted for age, gender, year, concomitant medication, and comorbidity, and additionally in a propensity scorematched analysis. Results: A total of 89,703 patients with average follow up of 5.0±3.5 years were included in this study. In the 56,044 patients receiving statins, 5698 (10%) had new-onset AF vs. 5010 (15%) in the 33,659 patients serving as controls. The adjusted Cox regression analysis showed significant reduction in new-onset AF (HR 0.83, 95% CI 0.80-0.87, p≤0.001) in statin users. Adjustment for propensity score yielded nearly identical results (HR 0.82, 95% CI 0.78-0.85, p≤0.001). Furthermore, patients compliant to statin treatment had significant reduction in new-onset AF (HR 0.84, 95% CI 0.80- 0.87, p≤0.001). Finally, simvastatin and atorvastatin were significantly more effective than pravastatin (both p≤0.01) in reducing new-onset AF. Conclusions: Statin therapy was significantly associated with less new-onset AF in a nationwide cohort of post-MI patients. Furthermore, statins showed a type-dependent effect in preventing new-onset AF. These results support the beneficial effect of statin therapy beyond lipid lowering in patients with MI and underline the importance of statin adherence and choice of statin type.

KW - Age Factors

KW - Aged

KW - Aged, 80 and over

KW - Atrial Fibrillation

KW - Chi-Square Distribution

KW - Comorbidity

KW - Denmark

KW - Female

KW - Heptanoic Acids

KW - Humans

KW - Hydroxymethylglutaryl-CoA Reductase Inhibitors

KW - Male

KW - Medication Adherence

KW - Middle Aged

KW - Multivariate Analysis

KW - Myocardial Infarction

KW - Polypharmacy

KW - Pravastatin

KW - Propensity Score

KW - Proportional Hazards Models

KW - Pyrroles

KW - Registries

KW - Retrospective Studies

KW - Risk Factors

KW - Sex Factors

KW - Simvastatin

KW - Time Factors

KW - Treatment Outcome

U2 - 10.1177/2047487312462804

DO - 10.1177/2047487312462804

M3 - Journal article

C2 - 23012689

SN - 2047-4873

VL - 21

SP - 330

EP - 338

JO - European Journal of Preventive Cardiology

JF - European Journal of Preventive Cardiology

IS - 3

ER -

Statins reduce new-onset atrial fibrillation in a first-time myocardial infarction population: a nationwide propensity score-matched study

Abstract

Keywords

Access to Document

Fingerprint

Cite this